SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce

SYNI stock fell to $0.000001 on 10 Feb 2026 during U.S. market hours on the PNK exchange, a near-total collapse from a previous close of $0.08. The drop shows extreme oversold conditions that can trigger a short-term bounce for active traders using tight risk rules. Volume is elevated at 5,229 shares versus a 50-day average of 260, underlining a liquidity spike. We frame this as an oversold bounce trade, not a buy-and-hold thesis, and note the stock trades in the United States in USD.

SYNI stock: Price action and volume

The intraday print at $0.000001 represents a -99.9988% move from the previous close of $0.08317158, with 5,229 shares traded and average volume 260. That gives a relative volume of 20.11, which often precedes volatile intraday reversals. For an oversold bounce strategy, the key is whether early buyers can sustain support above the print and lift volume above the current spike.

SYNI stock: Financials and valuation

Synvista Therapeutics, Inc. reports EPS -7.66 and a market capitalization of roughly $3.00 with 2,586,000 shares outstanding. The stock has no usable PE multiple given negative earnings and a near-zero price. The company lists 9 full-time employees and clinical-stage assets, which magnifies the risk that equity value can move in tiny absolute dollars but large percentage swings.

SYNI stock: Technicals and oversold setup

Technical feeds show data gaps, but the price collapse and heavy relative volume fit a textbook oversold bounce setup: extreme sell pressure, thin liquidity, and scope for short-covering or bargain hunting. Traders should use small position sizes, tight stop-losses, and target discrete levels on any rebound. We recommend a scalp horizon and stop-loss within single-digit multiples of the current print given binary risk.

SYNI stock: Pipeline and sector context

Synvista Therapeutics, Inc. works in Medical – Pharmaceuticals with Phase II-stage programs such as ALT-2074 and alagebrium addressing diabetic cardiovascular risk and diastolic heart failure. Small biopharma names in the healthcare sector can see outsized moves on clinical updates or funding news. Sector trends matter; a firm sector day can support short-term bounces in beaten-down names.

Meyka AI rates SYNI with a score out of 100

Meyka AI rates SYNI with a score out of 100: 62.62 (B) and suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model outputs for context only and are not financial advice.

SYNI stock: Risks, trade plan and price targets

Key risks include near-zero market cap ($3.00), negative EPS (-7.66), and extremely low liquidity. For an oversold bounce, a disciplined trade plan can target an initial scalp to $0.01 with a strict stop below the intraday print. Meyka AI’s scenario model projects $0.00050 as a recovery scenario, implying +49,900.00% from the current $0.000001 print; forecasts are model-based projections and not guarantees.

Final Thoughts

SYNI stock shows an extreme oversold environment on 10 Feb 2026 in U.S. market hours on the PNK exchange, trading at $0.000001 with a relative volume spike of 20.11. That set-up creates a high-risk, high-reward scalp opportunity for traders seeking a short-term oversold bounce. Position sizes should be small and stops tight because the company’s market cap is $3.00, EPS is -7.66, and liquidity is thin. Meyka AI’s forecast model projects a recovery scenario at $0.00050, implying +49,900.00% from the current print; forecasts are model-based projections and not guarantees. Given the model grade B (62.62) and the HOLD suggestion, our view is that SYNI may produce short-lived bounces but remains speculative. Investors seeking more depth can view additional SYNI data on the Meyka platform for live updates and risk controls. Remember these notes are market analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.